HARRIS R JEFFREY
Known title: DirectorCIK: 0001183645
HARRIS R JEFFREY's purchase track record
HARRIS R JEFFREY has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/29/2024 | AMN | $150K | -3.5% | -5.9% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMN | ▲ Buy | Option Exercise | 8,325 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 5,555 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 4,048 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 6,009 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 9,563 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 9,563 | $0 | 5/1/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 3,019 | $0 | 4/19/2025 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,681 | $0 | 4/19/2024 | View on chart |
| AMN | ▲ Buy | Open Market | 2,640 | $150K | 2/29/2024 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,458 | $0 | 4/21/2023 | View on chart |
| AMN | ▼ Sell | Gift | 855 | $0 | 11/8/2022 | View on chart |
| AMN | ▼ Sell | Gift | 217 | $0 | 11/7/2022 | View on chart |
| AMN | ▲ Buy | Option Exercise | 2,139 | $0 | 4/21/2022 | View on chart |
| AMN | ▼ Sell | Gift | 250 | $0 | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
AMN Healthcare Maintains Outperform Rating, Target Raised to $43
Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.
AMN Healthcare Maintains Outperform Rating, Target Raised to $43. Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.